Telisotuzumab vedotin

AbbVie submitted a Biologics License Application for Teliso-V, a first-in-class ADC targeting c-Met overexpressing NSCLC, based on Phase 2 LUMINOSITY trial data. If approved, it would address unmet needs in NSCLC treatment, offering hope for patients with poor prognosis.

AbbVie submitted a BLA to the FDA for accelerated approval of telisotuzumab vedotin (Teliso-V) in EGFR wild type, nonsquamous NSCLC with c-Met overexpression, supported by Phase 2 LUMINOSITY trial data. Teliso-V received FDA Breakthrough Therapy Designation in December 2021.

AbbVie submits Biologics License Application to USFDA for Telisotuzumab Vedotin (Teliso-V), an ADC for previously treated nonsquamous NSCLC with c-Met overexpression.

NSCLC, the most common lung cancer, has high mortality rates. c-Met protein overexpression in NSCLC is linked to poor prognosis. Telisotuzumab vedotin, targeting c-Met, shows promise for treating c-Met overexpressing NSCLC, with FDA Breakthrough Therapy Designation and ongoing Phase 3 trials.

AbbVie submits Biologics License Application to FDA for Teliso-V, an investigational treatment for previously treated non-small cell lung cancer with c-Met overexpression.

AbbVie submitted a Biologics License Application to the FDA for accelerated approval of Teliso-V, a first-in-class antibody-drug conjugate targeting c-Met overexpressing nonsquamous NSCLC. Supported by Phase 2 LUMINOSITY trial data, Teliso-V aims to address unmet needs in NSCLC treatment, potentially becoming the first approved therapy for this specific patient population.

AbbVie submitted a Biologics License Application for Teliso-V, a first-in-class therapy targeting c-Met overexpressing NSCLC, based on Phase 2 LUMINOSITY trial data. If approved, it would address unmet needs in NSCLC treatment, offering hope for patients with poor prognosis.

AbbVie submits Biologics License Application to FDA for Teliso-V, an ADC targeting c-Met overexpression in previously treated nonsquamous NSCLC, supported by Phase 2 LUMINOSITY trial data.

The global ADC market is rapidly expanding, driven by increasing demand for targeted therapies. Over 15 ADCs are approved, with more than 600 in clinical trials. At least 10 new approvals are expected in the next couple of years. Numerous ADC candidates are in pivotal stages, with over 20 in Phase 3 trials. Key drugs in late-stage trials include Ifinatamab deruxtecan, DP 303c, BL B01D1, 9MW 2821, Telisotuzumab vedotin, and Datopotamab deruxtecan.